Trials / Completed
CompletedNCT00004665
Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- National Center for Research Resources (NCRR) · NIH
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Evaluate the long-term safety and tolerance of a synthetic formulation of dehydroepiandrosterone, GL701, in patients with systemic lupus erythematosus who have completed a prior GL701 protocol.
Detailed description
PROTOCOL OUTLINE: Patients receive daily oral dehydroepiandrosterone for 12 months. The dose is adjusted based on disease activity and tolerance of treatment. Patients are followed every 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dehydroepiandrosterone |
Timeline
- Start date
- 1995-06-01
- First posted
- 2000-02-25
- Last updated
- 2005-06-24
Source: ClinicalTrials.gov record NCT00004665. Inclusion in this directory is not an endorsement.